港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

福建海西新药创制股份有限公司（临时代码）

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

香港流通股本：- -

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

市销率: - -

数据加载中...

总览公司新闻公告

海西新药(02637)拟全球发售1150万股预计10月17日上市

一图解码：海西新药过港交所聆讯仿创双轨驱动业绩稳增

新股消息 | 海西新药通过港交所聆讯，四款仿制药入选国家带量采购计划

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/91208/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"91208","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91208\",,,,,undefined,":{"symbol":"91208","market":"HK","secType":"STK","nameCN":"福建海西新药创制股份有限公司（临时代码）","latestPrice":0,"timestamp":1760083200000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":0,"latestTime":"10-10 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1760319000000},"marketStatusCode":7,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1760059800000,1760068800000],[1760072400000,1760083200000]],"volumeRatio":0,"lotSize":100,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91208\",,,,,undefined,":{"symbol":"91208","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91208\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91208\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91208\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91208\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2574906978","title":"海西新药(02637)拟全球发售1150万股 预计10月17日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2574906978","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574906978?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 07:09","pubTimestamp":1759964964,"startTime":"0","endTime":"0","summary":"发售价为每股发售股份69.88-86.40港元，每手50股，预期H股将于2025年10月17日上午九时正在联交所开始买卖。该公司在中国最大、增长最快的治疗领域拥有多元化的产品组合及管线。截至最后实际可行日期，该公司已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、神经系统疾病及炎症疾病的仿制药;根据灼识咨询的资料，该等治疗领域占2023年中国医药销售总额的25%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1352851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","91208"],"gpt_icon":0},{"id":"2572597714","title":"一图解码：海西新药过港交所聆讯 仿创双轨驱动 业绩稳增","url":"https://stock-news.laohu8.com/highlight/detail?id=2572597714","media":"IPO解码","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572597714?lang=zh_cn&edition=fundamental","pubTime":"2025-10-02 16:11","pubTimestamp":1759392676,"startTime":"0","endTime":"0","summary":"历经两次递表后，海西新药通过了港交所聆讯，并于9月29日更新了聆讯后招股书；由华泰国际和招银国际担任联席保荐人。海西新药在中国最大、增长最快的治疗领域拥有多元化的产品组合及管线。据披露，海西新药的业务采用了新颖的双轨模式，包括仿制药及在研创新药。于往绩记录期间，海西新药的收益来自13种获批准产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251002161231a4511084&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251002161231a4511084&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0821914370.USD","LU0886674414.USD","BK1610","BK1131","LU0048597586.USD","LU1242518931.SGD","LU0979878070.USD","LU1044875133.USD","LU0149534421.HKD","LU1048588211.SGD","LU0650527681.SGD","LU1282649067.USD","LU0197773673.USD","LU0918141887.USD","LU0634319403.HKD","80388","LU0197773160.USD","LU0169518387.USD","91208","LU0061477393.USD","SG9999001051.SGD","LU0577902371.SGD","LU2226246903.HKD","LU0359202008.SGD","LU0348825331.USD","LU1105468828.SGD","LU0251144936.SGD","LU0348814723.USD","LU0648948544.HKD","LU0516423174.USD","LU1051768304.USD","LU0762540952.USD","LU0084288322.USD","LU0630378429.USD","SG9999001846.SGD","LU0791591158.USD","IE00B3T34201.USD","02637","LU0577902538.SGD","HKXCY","LU0607220059.USD","LU0577902298.EUR","LU0762542818.HKD","LU2039709279.SGD","LU0831103253.SGD","LU0106959298.USD","00388","LU0417516902.SGD","LU0791590937.USD","HEXmain","LU0516422440.USD"],"gpt_icon":0},{"id":"2571369634","title":"新股消息 | 海西新药通过港交所聆讯，四款仿制药入选国家带量采购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2571369634","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571369634?lang=zh_cn&edition=fundamental","pubTime":"2025-09-30 06:29","pubTimestamp":1759184946,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所9月29日披露，福建海西新药创制股份有限公司通过港交所主板上市聆讯，华泰国际和招银国际为其联席保荐人。公司目前已就14款仿制药获得国家药监局批准，并建立拥有四款在研创新药的管线。仿制药上，在已获国家药监局批准的15款仿制药当中，有四款入选国家带量采购计划，并继续带来庞大的收益贡献。赛西福于2024年及截至2025 年5月31日止五个月分别为公司贡献收益人民币0.44亿元及人民币0.19亿元。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","91208"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}]}}